Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome

Shotaro Tatekawa; Koji Umemura; Ryuichi Fukuyama; Akio Kohno; Masafumi Taniwaki; Junya Kuroda; Yoshihisa Morishita

doi:10.1002/ccr3.284

Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome

Clin Case Rep. 2015 Jun;3(6):472-8. doi: 10.1002/ccr3.284. Epub 2015 Apr 22.

Authors

Shotaro Tatekawa¹, Koji Umemura², Ryuichi Fukuyama³, Akio Kohno², Masafumi Taniwaki⁴, Junya Kuroda⁴, Yoshihisa Morishita²

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine Kyoto, Japan ; Division of Hematology and Oncology, JA Aichi Konan Kosei Hospital Aichi, Japan.
² Division of Hematology and Oncology, JA Aichi Konan Kosei Hospital Aichi, Japan.
³ Department of Diagnostic Pathology, JA Aichi Konan Kosei Hospital Aichi, Japan.
⁴ Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine Kyoto, Japan.

Abstract

TAFRO syndrome have been proposed as a rare variant of Castleman's disease. This article reports a case of a 56-year-old man with TAFRO syndrome who was successfully treated with thalidomide in spite of the refractoriness to prednisolone and tocilizumab. Thalidomide may be one of the treatment options for TAFRO syndrome.

Keywords: Castleman's disease; Interleukin-6; TAFRO syndrome; thalidomide; tocilizumab; vascular endothelial growth factor.

Publication types

Case Reports